Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 5Tumor-Agnostic 3Thoracic 2Head & Neck 2Breast 2Sarcoma 1Other neoplasm 1Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Rogaratinib × Tumor-Agnostic × Clear all
NCT03517956 2022-07-14

ROCOCO

Bayer

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03788603 2021-03-29

Rogaratinib (BAY1163877) in Chinese Patients

Bayer

Phase 1 Completed
1 enrolled
Tumor-Agnostic

Neoplasms

NCT02592785 2018-04-18

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Bayer

Phase 1 Completed
9 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡